News

Lilly’s Cyramza hits first-line NSCLC trial targets

Lilly’s Cyramza hits first-line NSCLC trial targets

Lilly is gearing up to file Cyramza for first-line treatment of certain lung cancer patients, after new trial data showed that the drug significantly extended progression-free survival (PFS) in this setting.

Positive results for monthly HIV drug

Positive results for monthly HIV drug

Johnson & Johnson/ViiV’s once-monthly, injectable drug combination for HIV shows comparable efficacy to daily oral treatment in two trials.

Darolutamide submitted for EU approval

Darolutamide submitted for EU approval

Orion Corporation and Bayer have submitted a marketing application in Europe for use of darolutamide in patients with a certain type of prostate cancer.